Sponsor: AbbVie, Inc
Sponsor Study ID: M18-868
Study Title: A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868)
CTO #: 103792
NCT Number: NCT04928846
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: The primary objective is to determine if telisotuzumab vedotin improves progression-free survival (PFS) per ICR assessment and/or Overall Survival (OS) compared to docetaxel in the following nested populations: Subjects with c-Met high overexpressing, EGFR wildtype, nonsquamous NSCLC and all subjects with c-Met overexpressing, EGFR wildtype, nonsquamous NSCLC